Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium and Pemetrexed in NSCLC
NCT00365183Phase 2Terminated
- Sponsor
- Pharmacyclics
- Start
- Jun 2006
- Primary completion
- Jan 2008
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in non-small cell lung cancer (NSCLC), sponsored by Pharmacyclics. Started Jun 2006; status: terminated.
02
Drugs
motexafin gadolinium
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00365183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365183.